

PEB 26 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

Bruce S. Londa  
Londa and Gluck, LLP  
220 East 42nd Street, 30th Floor  
New York, New York 10017

In re Application of :  
ANKER et al.  
Application No.: 10/019,452 :  
PCT No.: PCT/EP00/02062 :  
Int. Filing Date: 09 March 2000 :  
Priority Date: 09 March 1999 :  
Attorney Docket No.: 101195-65 :  
For: THERAPY AND USE OF COMPOUNDS  
IN THERAPY

DECISION ON PETITION  
UNDER 37 CFR 1.137(b)

The petition to revive under 37 CFR 1.137(b) filed 19 October 2001 in the above-captioned application is hereby **GRANTED** as follows:

Applicants' statement that "the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional" meets the requirements of 37 CFR 1.137(b)(3).

A review of the application file reveals that applicants have submitted the basic national fee of \$445 and the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

This application is being forwarded to the United States Designated/Elected Office (US/DO/EO) for continued processing including the issuance of a Notification of Missing Requirements (Form PCT/DO/EO/905) indicating that an oath or declaration is required.

*Anthony Smith*  
Anthony Smith  
Attorney-Advisor  
PCT Legal Office  
Telephone: (703) 308-6314  
Facsimile: (703) 308-6459